Cellular and molecular mechanisms of PIK3CA-related vascular anomalies

The phosphoinositide 3-kinase (PI3K) pathway is a major mediator of growth factor signaling, cell proliferation and metabolism. Somatic gain-of-function mutations in PIK3CA, the catalytic subunit of PI3K, have recently been discovered in a number of vascular anomalies. The timing and origin of these...

Full description

Bibliographic Details
Main Authors: Timothy D Le Cras, Elisa Boscolo
Format: Article
Language:English
Published: Bioscientifica 2019-06-01
Series:Vascular Biology
Subjects:
Online Access:https://vb.bioscientifica.com/view/journals/vb/1/1/VB-19-0016.xml
id doaj-b60078ec21d04d9b8c6304ffc2d65d8e
record_format Article
spelling doaj-b60078ec21d04d9b8c6304ffc2d65d8e2020-11-25T01:41:52ZengBioscientificaVascular Biology2516-56582516-56582019-06-0111H33H40https://doi.org/10.1530/VB-19-0016Cellular and molecular mechanisms of PIK3CA-related vascular anomaliesTimothy D Le Cras0Elisa Boscolo1Division of Pulmonary Biology, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati Children’s Hospital, Cincinnati, Ohio, USAExperimental Hematology and Cancer Biology, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati Children’s Hospital, Cincinnati, Ohio, USAThe phosphoinositide 3-kinase (PI3K) pathway is a major mediator of growth factor signaling, cell proliferation and metabolism. Somatic gain-of-function mutations in PIK3CA, the catalytic subunit of PI3K, have recently been discovered in a number of vascular anomalies. The timing and origin of these mutations remain unclear although they are believed to occur during embryogenesis. The cellular origin of these lesions likely involves endothelial cells or an early endothelial cell lineage. This review will cover the diseases and syndromes associated with PIK3CA mutations and discuss the cellular origin, pathways and mechanisms. Activating PIK3CA ‘hot spot’ mutations have long been associated with a multitude of cancers allowing the development of targeted pharmacological inhibitors that are FDA-approved or in clinical trials. Current and future therapeutic approaches for PIK3CA-related vascular anomalies are discussed.https://vb.bioscientifica.com/view/journals/vb/1/1/VB-19-0016.xmlvascular malformationvascular anomalies
collection DOAJ
language English
format Article
sources DOAJ
author Timothy D Le Cras
Elisa Boscolo
spellingShingle Timothy D Le Cras
Elisa Boscolo
Cellular and molecular mechanisms of PIK3CA-related vascular anomalies
Vascular Biology
vascular malformation
vascular anomalies
author_facet Timothy D Le Cras
Elisa Boscolo
author_sort Timothy D Le Cras
title Cellular and molecular mechanisms of PIK3CA-related vascular anomalies
title_short Cellular and molecular mechanisms of PIK3CA-related vascular anomalies
title_full Cellular and molecular mechanisms of PIK3CA-related vascular anomalies
title_fullStr Cellular and molecular mechanisms of PIK3CA-related vascular anomalies
title_full_unstemmed Cellular and molecular mechanisms of PIK3CA-related vascular anomalies
title_sort cellular and molecular mechanisms of pik3ca-related vascular anomalies
publisher Bioscientifica
series Vascular Biology
issn 2516-5658
2516-5658
publishDate 2019-06-01
description The phosphoinositide 3-kinase (PI3K) pathway is a major mediator of growth factor signaling, cell proliferation and metabolism. Somatic gain-of-function mutations in PIK3CA, the catalytic subunit of PI3K, have recently been discovered in a number of vascular anomalies. The timing and origin of these mutations remain unclear although they are believed to occur during embryogenesis. The cellular origin of these lesions likely involves endothelial cells or an early endothelial cell lineage. This review will cover the diseases and syndromes associated with PIK3CA mutations and discuss the cellular origin, pathways and mechanisms. Activating PIK3CA ‘hot spot’ mutations have long been associated with a multitude of cancers allowing the development of targeted pharmacological inhibitors that are FDA-approved or in clinical trials. Current and future therapeutic approaches for PIK3CA-related vascular anomalies are discussed.
topic vascular malformation
vascular anomalies
url https://vb.bioscientifica.com/view/journals/vb/1/1/VB-19-0016.xml
work_keys_str_mv AT timothydlecras cellularandmolecularmechanismsofpik3carelatedvascularanomalies
AT elisaboscolo cellularandmolecularmechanismsofpik3carelatedvascularanomalies
_version_ 1725039206668959744